公开(公告)号：US20210322572A1

公开(公告)日：2021-10-21

申请号：US17244835

申请日：2021-04-29

申请人： Canji Inc.

发明人： William F. Benedict

IPC分类号： A61K48/00 ,  A61K9/00 ,  A61K9/127 ,  A61K38/21 ,  C07K14/56 ,  C12N15/86

摘要： The present invention provides a method for the treatment of “interferon resistant” tumors (i.e., tumors resistant to treatment with exogenously-administered interferon polypeptide) through the use of a non-replicating agent which induces human cells to express interferon species. In particular it is noted that inducing interferon expression in the patient's body possesses properties not associated with exogenously-produced intravenously-administered interferon proteins. The present invention further provides compositions useful in the treatment of cancer resistant to treatment with exogenous interferon polypeptide, by using a non-replicating agent which induces human cells to express interferon species, e.g., an antigenic, replication-deficient virus optionally carrying an interferon transgene.